Terremoto Biosciences

Catch up with the latest happenings at Terremoto.

Terremoto is seeking an Associate Director or Director of DMPK to support the discovery of small-molecule cancer therapeutics as part of its drug discovery team.

Terremoto is hiring a Buyer/Planner to plan and procure lab supplies, reagents, and capital equipment for its scientific team and manage supplier relationships, supplies, costs, inventory, and equipment.

Terremoto's team works to unlock covalent chemistry and explores new areas while supporting one another.

Associate Director, Finance & Accounting

Executive Director, Head of Technical Operations

Terremoto is developing targeted small-molecule medicines with optimized clinical profiles and therapeutic benefits.

The company lists its address as 230 East Grand Avenue, Suite 200, San Francisco, CA, 94080.

Terremoto says covalent chemistry enables it to deliver small-molecule medicines.

Terremoto Biosciences, Inc.'s Consumer Health Data Privacy Notice supplements its other privacy notices and applies to the collection of Consumer Health Data subject to state laws such as the Washington State My Health My Data Act.

Terremoto Biosciences, Inc.'s privacy notice describes the personal data and other information it collects through interactions and its services, and how it uses and shares that data with third parties.

Terremoto Biosciences, Inc.'s privacy notice covers patients and their caregivers, guardians, parents, or representatives, as well as health care and other medical professionals who provide personal information.

Terremoto Biosciences, Inc.'s privacy notice applies to job applicants, contractors, and employees who provide personal data in connection with work opportunities, employment decisions, or contracted work.

Warp Sciences Inc. launches a U.S.-based chemistry contract research organization, securing $215 million in funding. The startup specializes in lead optimization analog synthesis for biotech and pharmaceutical companies, using AI trained on physical lab data. Co-founder Kevin Weil, formerly OpenAI’s science chief, emphasizes the need for real-world chemistry data to advance AI in physical sciences. Warp aims to match overseas lab quality at competitive pricing, addressing concerns over intellectual property and geopolitical risks tied to outsourcing drug research to China.

Oct 2026SiliconANGLENews article

Terremoto Biosciences names **James Christensen, Ph.D.** as its new **Chief Executive Officer**. The appointment follows the company’s focus on advancing microbiome-based therapeutics. Christensen brings over two decades of biotech leadership experience, including roles at **Moderna** and **Genentech**. Terremoto specializes in developing precision microbiome solutions for metabolic and immune disorders.

Jul 2026Terremoto | A seismic shift is coming to drug development & discovery.News article

Terremoto Biosciences receives **FDA Fast Track designation** for **TER-2013**, an AKT1-selective small-molecule inhibitor targeting **HR+/HER2- breast cancer** with **AKT/PI3K/PTEN alterations**. The designation applies to patients who have progressed following **endocrine therapy and CDK4/6 inhibitor treatment**. TER-2013 aims to address resistance mechanisms in advanced breast cancer by selectively inhibiting AKT1 signaling pathways.

Jun 2026BioSpaceNews article

Terremoto Biosciences secures **$108 million in Series C funding** to develop **selective AKT1 inhibitors** for oncology and **Hereditary Hemorrhagic Telangiectasia (HHT)**. New investors—**RA Capital Management, Deep Track Capital, Osage University Partners (OUP), and BeOne Medicines**—join existing backers to accelerate clinical programs. The company targets precision therapies for AKT1-driven diseases, including rare genetic disorders and cancers.

Jun 2026Terremoto | A seismic shift is coming to drug development & discovery.News article